iTeos Therapeutics Inc. (ITOS) News

iTeos Therapeutics Inc. (ITOS): $25.36

1.66 (+7.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter ITOS News Items

ITOS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ITOS News Highlights

  • For ITOS, its 30 day story count is now at 3.
  • Over the past 23 days, the trend for ITOS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • APLS, BEAT and DRUG are the most mentioned tickers in articles about ITOS.

Latest ITOS News From Around the Web

Below are the latest news stories about iTeos Therapeutics Inc that investors may wish to consider to help them evaluate ITOS as an investment opportunity.

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Yahoo | February 24, 2022

iTeos to Participate in Upcoming Investor Conferences in February

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Feb. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will participate in two upcoming virtual investor conferences in February: 11th Annual SVB Leerink Global Healthcare ConferenceDate

Yahoo | February 10, 2022

Jackson Creek Investment Advisors LLC Buys ITeos Therapeutics Inc, Extreme Networks Inc, SMART ...

Investment company Jackson Creek Investment Advisors LLC (Current Portfolio) buys ITeos Therapeutics Inc, Extreme Networks Inc, SMART Global Holdings Inc, BlueLinx Holdings Inc, Newmark Group Inc, sells OptimizeRx Corp, Ranger Oil Corp, Ranger Oil Corp, Ranger Oil Corp, Digital Turbine Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Jackson Creek Investment Advisors LLC.

Yahoo | February 1, 2022

Asymmetry Capital Management, L.P. Buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, ...

Investment company Asymmetry Capital Management, L.P. (Current Portfolio) buys Biomarin Pharmaceutical Inc, UnitedHealth Group Inc, AbbVie Inc, IQVIA Holdings Inc, Centene Corp, sells Alkermes PLC, Medtronic PLC, Insulet Corp, Hologic Inc, Sage Therapeutics Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Asymmetry Capital Management, L.P..

Yahoo | January 19, 2022

iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 10, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today provided a clinical development plan for its anti-TIGIT monoclonal antibody, EOS-448, and its A2A receptor antagonist, inupadenant. iTeos also announced the promotion of Yvonne McGrath, Ph.D., to chief scie

Yahoo | January 10, 2022

Why iTeos Therapeutics Topped the Market Today

The stock market got off to a memorable start on the first trading day of 2022, but iTeos Therapeutics (NASDAQ: ITOS) had a particularly memorable day. After market hours on Friday S&P Dow Jones Indices, the company that operates the closely tracked set of S&P indexes, announced that iTeos would become a component of its S&P SmallCap 600 index. This is a potentially very lucrative arrangement, as it includes a $625 million upfront payment to iTeos, and potentially up to an additional $1.45 billion in developmental and commercial milestone payments.

Yahoo | January 3, 2022

iTeos to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2022 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Conference being held virtually on Tuesday, January 11, 2022 at 11:15 a.m. ET. A live

Yahoo | January 3, 2022

iTeos Therapeutics Set to Join S&P SmallCap 600

iTeos Therapeutics Inc. (NASD: ITOS) will replace Magellan Health Inc. (NASD: MGLN) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, January 5. S&P 500 constituent Centene Corp. (NYSE: CNC) is acquiring Magellan Health in a deal expected to be completed soon pending final conditions.

Yahoo | December 31, 2021

ITeos Therapeutics Inc Insiders are Selling. Investors Should Take Notice

GuruFocus data shows that Matthew Gall, CFO of ITeos Therapeutics Inc ( NA:ITOS), sold 5,000 shares on December 27, 2021.

Yahoo | December 29, 2021

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on iTeos Therapeutics (ITOS – Research Report) and Chinook Therapeutics (KDNY – Research Report) with bullish sentiments. iTeos Therapeutics (ITOS) Wedbush analyst David Nierengarten reiterated a Buy rating on iTeos Therapeutics on December 10 and set a price target of $48.00. The company's shares closed last Monday at $46.68, close to its 52-week high of $47.61. According to TipRanks.

Christine Brown on TipRanks | December 28, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5497 seconds.